Urinary System pp 438-450 | Cite as

Urinary Glycoproteins as Modulators of Calcific Nephrolithiasis

  • Fouad Atmani
  • Jayashree A. Gokhale
  • Saeed R. Khan
Part of the Monographs on Pathology of Laboratory Animals book series (LABORATORY)


Kidney stone formation (nephrolithiasis), a painful and debilitating malady, afflicts more than 1% of the population in industrialized nations and can persist with serious medical consequences throughout a patient’s lifetime. It is now widely recognized that kidneys normally produce urine that is supersaturated with respect to calcium oxalate (CaOx) and calcium phosphate, the most frequent components of urinary stones. However, even when these substances are present at a concentration exceeding their relative solubility, the formation of stones does not occur in normal urine. This observation allows us to hypothesize that “normal urine” contains substances calledinhibitors or modulators that prevent or reducecrystal formation and development of stones


Calcium Oxalate CaOx Crystal Urinary Trypsin Inhibitor Calcium Oxalate Crystallization Calcific Nephrolithiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson GAF, Bardet MI (1964) Prothrombin synthesis in dog. Am Physiol 206:929–938Google Scholar
  2. Aronson DL, Ball AP, Franza RB, Hugli TE, Fenton JW 2nd (1980) Human prothrombin fragments F1 (αß) and F2: preparation and characterization of structural and biological properties. Thromb Res 20:239–253PubMedCrossRefGoogle Scholar
  3. Asplin JR, DeGanelio S. Nakagawa Y, Coe FL (1991) Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261:F824-F830Google Scholar
  4. Asplin JR, Hoyer J. Gillespie C, Coe FL (1995) Uropontin (UP) inhibits aggregation of calcium oxalate monohydrate (COM) crystals. J Am Sci Nephrol 6:941Google Scholar
  5. Atmani F, Khan SR (1995) Characterization of uronicacid- rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 23:95–101PubMedCrossRefGoogle Scholar
  6. Atmani F, Lacour B, Drüeke T, Daudon M (1993a) Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urol Res 21:61–66PubMedCrossRefGoogle Scholar
  7. Atmani F, Lacour B, Strecker G, Parvy P, Drüeke T, Daudon M (1993b) Molecular characteristics of uronicacid- rich protein: a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun 191:1158–1165PubMedCrossRefGoogle Scholar
  8. Atmani F. Lacour B, Jungers P, Drüeke T, Daudon M (1994) Reduced inhibitory activity of uronic-acid-rich protein urine of stone formers. Urol Res 22:257–260PubMedCrossRefGoogle Scholar
  9. Atmani F, Opalko FJ, Khan SR (1995) Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res (in press)Google Scholar
  10. Atmani F, Mizon J, Khan SR (1996a) Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-x-inhibitor. Eur J Biochem 236:984–990PubMedCrossRefGoogle Scholar
  11. Atmani F, Opalko FJ, Khan SR (1996b) Association of urinary macromolecules with calcium oxylate crystalsinduced in vitro in normal human and rat urine. Urol Res (in press)Google Scholar
  12. Bachmann S, Metzger R, Bunnemann B (1990) Tamm Horsfall protein-mRNA synthesis is localized to the thick ascending limb of Henle’s loop in rat kidney. Histochemistry 94:517–523PubMedCrossRefGoogle Scholar
  13. Balduyck M, Laroui S, Mizon C, Mizon J (1989) A proteoglycan related to the urinary trypsin inhibitor (UTI) links the two heavy chains of inter-alpha-trypsin inhibitor. Biol Chern Hoppe-Seyler 370:331–336Google Scholar
  14. Bezeaud A, Guillin MC (1984) Quantitation of prothrombin activation products in human urine. Br J Haematol 58:579–606CrossRefGoogle Scholar
  15. Bichler KH, Kirchner CH, Ideler V (1976) Uromucoid excretion of normal individuals and stone formers. Br J Urol47:733–737CrossRefGoogle Scholar
  16. Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW (1993) Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 22:147–159PubMedCrossRefGoogle Scholar
  17. Bourguignon J, Sesboüé R, Diarra-Mehrpour M, Daveau M, Martin JP (1989) Human inter-α-trypsin inhibitor. Synthesis and maturation in hepatoma HepG2 cells. Biochem J 261:305–308PubMedGoogle Scholar
  18. Brown LF, Berse B, Water LVD, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169–1180PubMedGoogle Scholar
  19. Businaro R, Leali FMT, DeRenzis G, Pompili E, Pagliari G, Menghi G, Fumagalli L (1992) Inter-alpha-trypsin inhibitor-related immunoreactivity in human tissues and body fluids. Cell Mol Biol38:43~71Google Scholar
  20. Chalko C, Krishna G, Hoyer JR, Goldfarb S (1992) Characterization of urinary uropontin excretion in humans. J Am Soc Nephrol 3:681Google Scholar
  21. Chang PL, Prince CW (1991) 1α,25-Dihydroxyvitamin D3 stimulates synthesis and secretion of nonphophorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res 51:2144–2150PubMedGoogle Scholar
  22. Chawla RK, Wadsworth AD, Rudman D (1978) Relation of the urinary cancer-related glycoprotein EDC1 to plasma inter-α-trypsin inhibitor. J Immunol 121:1636–1639PubMedGoogle Scholar
  23. Colette C, Benmbarek A, Boniface H, Astre C, ParesHerbute N, Monnier L, Guitter J (1991) Determination of protein-bound urinary gamma-carboxyglutamic acid in calcium nephrolithiasis. Clin Chim Acta 204:43–50PubMedCrossRefGoogle Scholar
  24. Craig AM, Smith JH, Denhardt DT (1989) Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12–0-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chern 264:9682–9689Google Scholar
  25. Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7:1475–1482PubMedGoogle Scholar
  26. Desbois C, Hogue DA, Karsenty G (1994) The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chern 269:1183–1190Google Scholar
  27. Dietl T, Dobrinski W, Hochstrasser K (1979) Human intera-trypsin inhibitor. Limited proteolysis by trypsin, plasmin, kallikrein and granulocytic elastase and inhibitory properties of the cleavage products. Hoppe-Seyler Z Physiol Chern 360:1313–1318CrossRefGoogle Scholar
  28. Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chern 37:1589–1594Google Scholar
  29. Doyle IR, Marshall VR, Dawson CJ, Ryall RL (1995) Calcium oxalate crystal matrix extract: the most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro. Urol Res 23:53–62PubMedCrossRefGoogle Scholar
  30. Feuchuck DM, Robertson WG, Hughes H (1994) Nephrocalcin in Saudi Arabian stoneformers and controls. In: Ryall RL, Bais R, Marshall VR, Rofe AM, Smith LH, Walker VR (eds) Urolithiasis 2. Plenum, New York, pp 299–301Google Scholar
  31. Fisher LW, Hawkins GR, Tuross N, Termine JD (1987) Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chern 262:9702–9708Google Scholar
  32. Fletcher AP, McLaughlin JE, Ratcliffe WA, Woods PA (1970) The chemical composition and electron microscopic appearance of a protein derived from urinary casts. Biochim Biophys Acta 214:299–308PubMedGoogle Scholar
  33. Fraij BM (1989) Separation and identification of urinary proteins and stone-matrix proteins by mini-slab sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Clin Chern 35:658–662Google Scholar
  34. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz S, Johnson RJ (1994) Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 45:515–524PubMedCrossRefGoogle Scholar
  35. Gokhale JA, Glenton GA, Khan SR (1997) Localization of Tamm-Horsfall protein and osteopontin in a rat nephrolithiasis model.Google Scholar
  36. Grant AM, Baker LR, Neuberger A (1973) Urinary Tamm-Horsfall glycoprotein in certain kidney diseases and its content in renal and bladder calculi. Clin Sci 44:377–384PubMedGoogle Scholar
  37. Hallson PC, Rose GA (1979) Uromucoids and urinary stone formation. Lancet 1:1000–1002PubMedCrossRefGoogle Scholar
  38. Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMedGoogle Scholar
  39. Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins Am J Physiol 257:F99-F106PubMedGoogle Scholar
  40. Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMedGoogle Scholar
  41. Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784-F791PubMedGoogle Scholar
  42. Hess B, Jaggi M, Zipperle L, Jaeger P (1995) Reduced carbohydrate content of Tamm-Horsfall glycoprotein (THP) from severely recurrent renal calcium stone formers (RCSF). Am Soc Nephrol 6:949Google Scholar
  43. Hoyer JR (1994) Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 20:385–392PubMedGoogle Scholar
  44. Hoyer JR, Seiler MW (1979) Pathophysiology of Tamm Horsfall protein. Kidney Int 16:279–289PubMedCrossRefGoogle Scholar
  45. Jessen TE, Faarvang KL, Ploug M (1988) Carbohydrate as covalent crosslink in human inter-α-trypsin inhibitor: a novel plasma protein structure. FEBS Lett 230:195–200PubMedCrossRefGoogle Scholar
  46. Jonsson-Berling BM, Ohlsson K, Rosengren M (1989) Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chern Hoppe Seyler 370:1157–1161CrossRefGoogle Scholar
  47. Kitamura T, Pak CYC (1981) Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro. J Urol 127:1024–1026Google Scholar
  48. Kleinman JG, Beshensky AM, Worcester EM, Brown D (1995) Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 47:1585–1596PubMedCrossRefGoogle Scholar
  49. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Susuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chern 268:15180–15184Google Scholar
  50. Kok DJ, Papapoulos SE, Bijvoet OL (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet 1:1056–1058PubMedCrossRefGoogle Scholar
  51. Kumar S, Muchmore A (1990) Tamm-Horsfall protein - uromodulin (1950–1990). Kidney Int 37:1395–1401PubMedCrossRefGoogle Scholar
  52. Kumar S, Jasani B, Hunt JS, Moffat DB, Asscher A W (1985) A system for accurate immunolocalization of Tamm-Horsfall protein in renal biopsies. Histochem 17:1251–1258CrossRefGoogle Scholar
  53. Lieske JC, Leonard R, Toback FG (1995) Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 268:F604-F612PubMedGoogle Scholar
  54. Lopez M, Nakagawa Y, Coe FL, Tsai C, Michael AF, Scheinman 11 (1986) Immunochemistry of urinary calcium oxalate crystal growth inhibitor (CGI). Kidney Int 29:829–833PubMedCrossRefGoogle Scholar
  55. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT (1993) Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 69:355–363PubMedGoogle Scholar
  56. Malki N, Balduyck M, Maes P, Capon C, Mizon C, Han KK, Tartar A, Fournet B, Mizon J (1992) The heavy chains of human plasma inter-α-trypsin inhibitor: their isolation, their identification by electrophoresis and partial sequencing. Biol Chern Hoppe-Seyler 373:1009–1018CrossRefGoogle Scholar
  57. McKee MD, Nanci A, Landis WJ, Gotoh Y, Gerstenfeld LC, Glimcher MJ (1990) Developmental appearance and ultrastructural immunolocalization of a major 66kDa phosphoprotein in embryonic and post-natal chicken bone. Anat Rec 228:77–92PubMedCrossRefGoogle Scholar
  58. McKee MD, Nanci A, Khan SR (1994) Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913–1929CrossRefGoogle Scholar
  59. Morelle W, Capon C, Balduyck M, Sautiere P, Kauach M, Michalski C, Fournet B, Mizon J (1994) Chondroitin sulfate covalently cross-links the three polypeptide chains of inter-α-trypsin inhibitor. Eur J Biochem 221:881–888PubMedCrossRefGoogle Scholar
  60. Nagata T, Bellows CG, Kasugai S, Butler WT, Sodek J (1989) Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-I osteopontin), BSP 9 bone sialoprotein and SPARC (osteonectin)] in association with mineralized- tissue formation by fetal-rat calvarial cells in culture. Biochem J 174:513–520Google Scholar
  61. Nakagawa Y, Margolis HC, Yokoyama S, Kezdy FJ, Kaiser ET, Coe FL (1981) Purification and characterization of calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chern 256:3936–3644Google Scholar
  62. Nakagawa Y, Abram V, Kezdy FJ, Kaiser ET, Coe FL (1983) Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chern 258:12594–12600Google Scholar
  63. Nakagawa Y, Abram V, Coe FL (1984) Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol 247:F765-F772PubMedGoogle Scholar
  64. Nakagawa Y, Abram V, Parks JH, Lau HSH, Kawooya JK, Coe FL (1985) Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 76:1455–1462PubMedCrossRefGoogle Scholar
  65. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FI (1987) Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in y-carboxyglutamic acid. J Clin Invest 79:1782–1787PubMedCrossRefGoogle Scholar
  66. Nakagawa Y, Otsuki T, Coe FL (1989) Elucidation of multiple forms of nephrocalcin by 31p_NMR spectrometer. FEBS Lett 250:187–190PubMedCrossRefGoogle Scholar
  67. Nakagawa Y, Netzer M, Coe FL (1990) Immunohistochemical localization of nephrocalcin (NC) to proximal tubule and thick ascending limb of Henle’s loop (TAHL) of human and mouse kidney: resolution of a conflict. Kidney Int 37:474 (abstr)Google Scholar
  68. Nakagawa Y, Renz CL, Ahmed M, Coe FL (1991) Isolation of nephrocalcin from kidney tissue of nine vertebrates species. Am J Physiol 260:F243-F248PubMedGoogle Scholar
  69. Nomura S, Wills AJ, Edwards DR, Heath JK, Hogan BLM (1988) Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J Cell Biochem 106:441–450Google Scholar
  70. Odum L (1989) Immunohistochemical investigation of inter- a-trypsin inhibitor in urinary tract. APMIS 97:375–360CrossRefGoogle Scholar
  71. Odum L (1991) Investigation of inter-α-trypsin inhibitorand slow migrating proteinase inhibitors in serum and urine. Dan Med Bull 38:68–77PubMedGoogle Scholar
  72. Odum L, Hansen-Nord G, Byrjalsen I (1987) Human inter-α-trypsin inhibitor and immunologically related inhibitors investigated by quantitative immunoelectrophoresis. II. Pathological conditions. Clin Chim Acta 162:189–198PubMedCrossRefGoogle Scholar
  73. Oldberg A, Franzen A, Heinegard D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) CDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83:8819–8823PubMedCrossRefGoogle Scholar
  74. Potempa J, Kwon K, Chawla R, Travis J (1989) Inter-atrypsin inhibitor. Inhibition spectrum of native and derived forms. J Biol Chern 264:15109–15114Google Scholar
  75. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, Schrohenloher RE (1987) Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chern 262:2900–2907Google Scholar
  76. Rose GA, Sulaiman S (1982) Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies. J Urol127:177–179PubMedGoogle Scholar
  77. Rose FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz HA, Robey PG, Teitelbaum SL, Cheresh DA (1993) Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin vB3 potentiate bone resorption. J Biol Chern 268:9901–9907Google Scholar
  78. Ryall RL, Harnett RM, Hibberd CM, Edyvane KA, Marshall VR (1991) Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on oxalate crystallization in undiluted human urine. Urol Res 19:181–188PubMedCrossRefGoogle Scholar
  79. Salier JP, Sesboüé R, Vercaigne D, Bourguignon J, Martin JP (1983) Inter-alpha-trypsin inhibitor (ITI): use of a new antisera for qualitative studies and discretequantitation of ITT and its derivatives. Ann Biochem 133:336–343CrossRefGoogle Scholar
  80. Salier JP, Diarra-Mehrpour M, Sesbolie R, Bourguignon J, Benarous R, Ohkubo I, Kurachi S, Kurachi K, Martin JP (1987) Isolation and characterization of cDNAs encoding the heavy chain of human inter-alpha-trypsin inhibitor (ITT): unambiguous evidence for multipolypeptide chain structure of ITI. Proc Natl Acad Sci USA 84:8272- 8276PubMedCrossRefGoogle Scholar
  81. Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone former, and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRefGoogle Scholar
  82. Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. III. Studies on the role of Tamm-Horsfall mucoprotein and of ionic strength. J Urol 136:505–507PubMedGoogle Scholar
  83. Shiba KS, Kanamori K, Cho H, Furuhata N, Harada T, Shiba A, Nakao M (1988) Re-evaluation of normal human urinary proteins fractionated by one-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Clin Chim Acta 172:77–84PubMedCrossRefGoogle Scholar
  84. Shiraga H, Min W, Vandusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430PubMedCrossRefGoogle Scholar
  85. Neilson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Nat! Acad Sci USA 89:426–430PubMedCrossRefGoogle Scholar
  86. Sikri KL, Foster CL, MacHugh N, Marshall RD (1981) Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immunoelectron microscopical techniques. J Anat 132:597–605PubMedGoogle Scholar
  87. Singh K, DeVouge MW, Mukherjee BB (1990) Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chern 265:18696–18701Google Scholar
  88. Sirivongs D, Nakagawa Y, Vishny WK, Favus MJ, Coe FL (1989) Evidence that mouse renal proximal tubule cells produce nephrocalcin. Am J Physiol 257:F390-F398PubMedGoogle Scholar
  89. Sjoberg EM, Fries E (1992) Biosynthesis of bikunin (urinary trypsin inhibitor) in rat hepatocytes. Arch Biochem Biophys 295:217–222PubMedCrossRefGoogle Scholar
  90. Sorensen S, Hansen K, Bak S, Justesen SJ (1990) An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18:373–379PubMedCrossRefGoogle Scholar
  91. Stapleton AM, Ryall RL (1994) Crystal matrix protein - getting blood out of a stone. Miner Electrolyte Metab 20:399–409 PubMedGoogle Scholar
  92. Stapleton AM, Seymour AE, Brennan JS, Doyle IR, Marshall VR, Ryall RL (1993a) Immunohistochemicaldistribution and quantification of crystal matrix protein. Kidney Int 44:817–824PubMedCrossRefGoogle Scholar
  93. Stapleton AM, Simpson RJ, Ryall RL (1993b) Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun 195:1199–1203PubMedCrossRefGoogle Scholar
  94. Steinbuch M (1976) The inter-α-trypsin inhibitor. Methods Enzymol45:760–772PubMedCrossRefGoogle Scholar
  95. Stevenson FK, Cleave AJ, Kent PW (1971) The effect of ions on the viscometric and ultracentrifugal behavior of Tamm-Horsfall glycoprotein. Biochim Biophys Acta 236:59–66PubMedGoogle Scholar
  96. Suzuki K, Moriyama M, Nakajima C, Kawamura K, Miyazawa K, Tsugawa R, Kikuchi N, Nagata K (1994) Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin. Urol Res 22:45–50PubMedCrossRefGoogle Scholar
  97. Tang Y, Grover PK, Moritz RL, Simpson RJ, Ryall RL (1995) Is nephrocalcin related to the urinary derivative (bikunin) of inter-α-trypsin inhibitor? Br J Urol 75:425- 430CrossRefGoogle Scholar
  98. Toki N, Sumi H (1982) Urinary trypsin inhibitor and urokinase activities in renal diseases. Acta Haematol 67:109–113PubMedCrossRefGoogle Scholar
  99. Trefz G, Streit B, Justus CW, Ebert W, Kramer MD (1991) Establishment of an enzyme-linked Immunosorbent assay for urinary trypsin inhibitor by using a monoclonal antibody. J Immunoassay 12:347- 369PubMedCrossRefGoogle Scholar
  100. Wabner CL, Sirivongs D, Maikranz P, Nakagawa Y, Coe FL (1987) Evidence for increased excretion in pregnancy of nephrocalcin, a ruinary inhibitor of calcium oxalate crystal growth. Kidney Int 31:359Google Scholar
  101. Waterhouse P, Parhar RS, Guo X, Lala PK, Denhardt DT (1992) Regulated temporal and spatial expression of the calcium-binding proteins calycin and OPN (osteopontin) in mouse tissues during pregnancy. Mol Reprod Dev 32:315–323PubMedCrossRefGoogle Scholar
  102. Worcester EM, Nakagawa Y, Wabner CL, Kumar S, Coe FL (1988) Crystal absorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol 255:F1197-F1205PubMedGoogle Scholar
  103. Worcester EM, Lemann JJ, Gray RW (1989) Effect of calcitriol administration on urinary excretion of nephrocalcin, a calcium-oxalate crystal-growth inhibitor. Proc Cong Vancouver, pp 255–257Google Scholar
  104. Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029- 1036PubMedCrossRefGoogle Scholar
  105. Worcester EM, Sebastian JL, Hiatt JG. Beshensky AM, Sadowski JA (1993) The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53:242–248CrossRefGoogle Scholar
  106. Worcester EM, Snyder C, Beshensky AM (1995) Osteopontin inhibits heterogeneous nucleation of calcium oxalate. J Am Soc Nephrol 6:956Google Scholar
  107. Yoshioka T, Koide T, Utsunomiya M, Itatani H, Oka T, Sonoda T (1989) Possible role of Tamm-Horsfall glycoprotein calcium oxalate crystallization. Br J Urol 64:463–467PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Fouad Atmani
  • Jayashree A. Gokhale
  • Saeed R. Khan

There are no affiliations available

Personalised recommendations